2seventy Bio stops enrolling patients in blood cancer therapy study

 2seventy bio (TSVT.O) will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb(BMY.N) for treating patients with newly diagnosed multiple myeloma.